Eli Lilly (NYSE:LLY) believes that its diabetes medicine Mounjaro (tirzepatide) will acquire a further indication to deal with weight problems as early as the top of this 12 months, in keeping with CFO Anat Ashkenazi.

Talking on the J.P. Morgan Healthcare Convention, Ashkenazi added that the corporate is constructing a “nicely of proof” to show that Mounjaro can do extra than simply assist people shed weight. This contains information on advantages for obstructive sleep apnea, coronary heart failure, and kidney illness.

Ashkenazi hinted that this information might be used to distinguish Mounjaro from Novo Nordisk’s (NVO) Wegovy (semaglutide).

In a part 3 trial, tirzepatide bested semaglutide when it comes to A1C and weight reductions.

Lilly is ready for US FDA motion on its rolling submission for the burden loss indication.

Mounjaro as a weight reduction drug might additionally profit if the Deal with and Scale back Weight problems Act is handed, Ashkenazi famous. The laws would cowl continual weight administration medication for Medicare enrollees.

She added that Lilly is anticipating the launch of 4 new molecular entities this 12 months: donanemab (Alzheimer’s illness), lebrikizumab (atopic dermatitis), mirikizumab (ulcerative colitis), and pirtobrutinib (mantle cell lymphoma).

Learn why In search of Alpha contributor Jacob Braun sees Lilly (LLY) as a promote due to its excessive valuation.